8-K: 4D Molecular Therapeutics Reports Positive 4D-150 Wet AMD Data

4D Molecular Therapeutics announced positive interim 1.5to 3.5-year data from its Phase 1/2 PRISM clinical trial for 4D-150 in wet age-related macular degeneration, alongside a preliminary cash estimate of $372.2 million.

Summary

• 4D Molecular Therapeutics estimates its cash, cash equivalents, and marketable securities at approximately $372.2 million as of September 30, 2025, noting this is a preliminary estimate subject to final closing procedures.
• The company announced positive interim 1.5to 3.5-year data from the Phase 1/2 PRISM clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD), with a data cutoff of August 22, 2025.
• Patients consistently maintained visual acuity and control of retinal anatomy (central subfield thickness) through up to 2 years.
• A clinically meaningful reduction in supplemental anti-VEGF injections was observed across all cohorts, with the Phase 2b recently diagnosed subgroup showing a 92% reduction through 1.5 years compared to projected aflibercept 2mg Q8 weeks.
• Durability of disease control was maintained consistently across 6-month intervals through up to 2 years of follow-up.
• The Phase 3 dose (3E10 vg/eye) demonstrated a consistent and superior dose response on treatment burden reduction compared to the lower dose (1E10 vg/eye).
• 4D-150 was well tolerated, with only 2.8% (2 of 71) of patients receiving the Phase 3 dose experiencing mild (1+) intraocular inflammation within the first 6 months, which was transient and noted at a single timepoint.
• No new cases of inflammation were observed after 28 weeks, with approximately 1.5 to more than 3.5 years of follow-up.
• 99% of patients completed steroid prophylaxis taper on schedule and remained completely off steroids.
• No 4D-150-related hypotony, endophthalmitis, vasculitis, occlusive/non-occlusive retinal vasculitis, or choroidal effusions have been observed to date.

Sentiment

Score: 9

Explanation: The filing reports highly positive interim clinical trial data for 4D-150 in wet AMD, demonstrating strong efficacy in reducing treatment burden and maintaining visual acuity and retinal anatomy, coupled with a favorable safety profile over an extended period. This significantly de-risks the program and supports its advancement. The strong cash position also provides financial stability.

Positives

• Positive interim 1.5to 3.5-year data for 4D-150 in wet AMD, demonstrating sustained efficacy and durable disease control.
• Consistent maintenance of visual acuity and control of retinal anatomy (central subfield thickness) through up to 2 years.
• Significant and clinically meaningful reduction in supplemental anti-VEGF injections, with the Phase 2b recently diagnosed subgroup achieving a 92% reduction through 1.5 years.
• Durability of disease control was maintained consistently across 6-month intervals through up to 2 years.
• The Phase 3 dose (3E10 vg/eye) showed superior treatment burden reduction compared to the lower dose (1E10 vg/eye).
• 4D-150 was well tolerated with a favorable safety profile; only 2.8% of patients experienced mild, transient intraocular inflammation, with no new cases after 28 weeks.
• 99% of patients completed steroid prophylaxis taper on schedule and remained completely off steroids.
• Absence of severe ocular adverse events such as hypotony, endophthalmitis, or vasculitis.
• Strong preliminary cash position with an estimated $372.2 million in cash, cash equivalents, and marketable securities as of September 30, 2025.

Risks

• The estimated cash, cash equivalents, and marketable securities balance of $372.2 million is preliminary and subject to completion of financial closing procedures and management reviews, meaning the actual balance may vary.
• The preliminary cash estimate is not a comprehensive statement or estimate of the company's financial results or financial condition as of September 30, 2025.

Future Outlook

The filing highlights that the Phase 2b subgroup of recently diagnosed patients is most comparable to the cohort in the Phase 3 4FRONT clinical trials, suggesting a clear path and strong potential for 4D-150 to advance into later-stage development. The positive interim data supports the prospect of 4D-150 providing sustained, durable disease control with a significantly reduced treatment burden.

Management Comments

• 4D-150 continues to be well tolerated.

Industry Context

Wet age-related macular degeneration (wet AMD) remains a leading cause of blindness, with current standard-of-care anti-VEGF treatments requiring frequent intravitreal injections, which impose a significant burden on patients and healthcare systems. Gene therapies like 4D-150 aim to offer a transformative solution by providing long-term, durable disease control with potentially a single administration, thereby reducing treatment frequency and improving patient quality of life. The positive long-term data for 4D-150 positions it as a strong contender in the competitive ophthalmology gene therapy landscape, where several companies are pursuing similar long-acting or gene therapy approaches for retinal diseases.

Comparison to Industry Standards

• The 92% reduction in supplemental anti-VEGF injections for the recently diagnosed Phase 2b subgroup through 1.5 years, compared to projected aflibercept 2mg Q8 weeks, represents a significant improvement in treatment burden. Standard anti-VEGF therapies like aflibercept (Eylea) and ranibizumab (Lucentis) typically require injections every 4-8 weeks, while newer agents like faricimab (Vabysmo) extend intervals up to 16 weeks. 4D-150's data suggests a potential for even greater extension, moving towards a single-administration gene therapy model.
• The safety profile, with only 2.8% mild, transient intraocular inflammation and no severe ocular adverse events, compares favorably to other gene therapy candidates or even some long-acting anti-VEGF agents which can have inflammation concerns. For example, some gene therapies in development have faced challenges with inflammation or immune responses requiring more intensive steroid regimens.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical trial results, de-risking the lead asset and potentially increasing future valuation.
• Patients with wet AMD: Potential for a transformative treatment that significantly reduces the burden of frequent injections while maintaining efficacy and safety.
• Healthcare Providers: Potential for a new, more convenient treatment option for wet AMD patients.

Next Steps

• Further development and progression of 4D-150 towards Phase 3 clinical trials, as the Phase 2b subgroup is noted as comparable to the Phase 3 4FRONT trial cohort.
• Completion of financial closing procedures for the September 30, 2025, cash, cash equivalents, and marketable securities balance.

Key Dates

Recommendation

The positive interim 1.5to 3.5-year data for 4D-150 in wet AMD, particularly the significant reduction in treatment burden (up to 92% fewer injections) and favorable safety profile, represents a major de-risking event for 4D Molecular Therapeutics' lead asset. The data supports the potential for 4D-150 to be a best-in-class gene therapy for wet AMD, addressing a large market with high unmet needs for durable, less burdensome treatments. The strong cash position further supports continued development. This positive clinical update is highly likely to drive significant investor interest and a re-rating of the stock.

Keywords

4D Molecular Therapeutics, FDMT, 4D-150, Wet AMD, Age-related macular degeneration, Gene therapy, Ophthalmology, Clinical trial, Phase 1/2 PRISM, Anti-VEGF, Retinal disease, Biotechnology, Pharmaceutical, SEC filing, 8-K